HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $64

Benzinga · 10/16 10:35
HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $60 to $64.